Is 30 mL Cerebrolysin a Safe and Effective Drug for Improving Global and Cognitive Function in Patients with Alzheimer's Disease Aged 50 Years and Older with No Significant Comorbidities?

نویسنده

  • Anthony Champion
چکیده

OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use of 30 mL Cerebrolysin is a safe and effective drug for improving global and cognitive function in patients with Alzheimer’s Disease aged 50 years and older with no significant comorbidities. STUDY DESIGN: Systematic review of three randomized controlled trials published between 2001-2006, all English language. DATA SOURCES: Three randomized controlled trials comparing the efficacy of cerebrolysin to placebo in the treatment of individuals ages 50 and over with AD related cognitive and global functioning decline. All articles found using PubMed. OUTCOMES MEASURED: Three randomized controlled studies measured improvement in cognitive and global impairment in patients with AD using a combination of either ADAScog(clinician rated test measuring cognitive function), CIBIC+(clinician based interview of patient to assess global change), or CGI(clinician assessment of mental deterioration). The evaluations cover orientation, memory, language, understanding, behavior, and activities of daily living. Evaluations with the tests mentioned were made under double-blind conditions. RESULTS: Three randomized controlled trials were included in this review. Ruether et al. revealed a significant effect on functional and cognitive decline with 30mL Cerebrolysin. Panisset et al. found a significant relationship between Cerebrolysin and improved global functioning, but no change in cognition between experimental and control groups. Alverez et al. found insignificant effects on both cognition and global functioning. CONCLUSIONS: The results of the three studies represent inconclusive evidence that Cerebrolysin has significant effects on cognition and global functions in patients with AD. One study found significant improvements in cognition and global function, but the other studies found insignificant effects. Further studies are encouraged to develop a definitive relationship.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cognitive Rehabilitation An Effective Intervention to Decrease the Cognitive Deficits in Older Adults With Alzheimer Disease

Objectives: The aim of present study was to investigate the effect of cognitive rehabilitation, a new and non-pharmacological approach to reduce memory and other cognitive deficits in Alzheimer's disease. Methods & Materials: This study was a quasi-experimental research, in singlesubject study-with control group- and based on an A-B design. That was conducted in two groups of control and exp...

متن کامل

ASSESSMENT OF PHYSICAL FUNCTIONING AND ITS CORRELATES IN ADULTS 50 YEARS AND OLDER IN BUKAN, NORTHWEST OF IRAN; A CROSS-SECTIONAL STUDY

Background & Aims: Aging is associated with gradual erosive changes in the physiological function of many systems of the body. Ths study aimed to examine the physical functioning and limitation and its related factors in people aged 50 and older in Bukan, 2017. Materials & Methods: In this cross-sectional study 1201 elderly people aged 50 years and up were recruited from health recentres in Bu...

متن کامل

Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.

Dementia is the result of various cerebral disorders, leading to an acquired loss of memory and impaired cognitive ability. The most common forms are Alzheimer's disease (AD) and vascular dementia (VaD). Neurotrophic factors are essential for the survival and differentiation of developing neurons and protecting them against damage under pathologic conditions. Cerebrolysin is a peptide preparati...

متن کامل

Effects of N-PEP-12 on memory among older adults.

N-PEP-12 is a derivative of cerebrolysin, a brain-derived neuropeptide compound that has been approved for the treatment of Alzheimer's disease (AD) in more than 30 countries. N-PEP-12 is much less potent than cerebrolysin but it can be administered orally whereas the parent compound must be administered through multiple intravenous infusions. This study was undertaken to determine whether N-PE...

متن کامل

The role of genetics in alzheimer’s disease

Alzheimer's disease is a progressive neurological disorder that causes the brain to shrink (atrophy) and brain cells die. Alzheimer's disease is the most common cause of dementia and causes a decrease in thinking skills and social behaviors. Alzheimer's disease is more common in people over 65 years old. The risk of developing Alzheimer's disease and other types of dementia increases with age,...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2015